Analysts Expect Drug Supplier Whiplash To Endure on Rebate Changes

Analysts agree Trump’s prescription drug plans look ugly -- but they are divided on the real financial impact of the changes on the pharmaceutical supply chain.

While Jefferies expects the rebates debate to be an overhang, they only see a “modestly negative” impact in the worst case scenario, with Medicare beneficiaries and the federal government shouldering the bulk of the costs if rebates were eliminated.